We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As accusations fly that the Trump administration passed on securing doses of Pfizer’s highly effective COVID-19 vaccine beyond an initial supply contract, the president signed an executive order Tuesday that intends to prioritize American access to vaccines supported or procured by the government and threatened to invoke emergency legislation, if needed, to bolster supplies. Read More
Beckton Dickinson (BD) has announced that it is investing $1.2 billion over four years toward strengthening its manufacturing capabilities for future pandemic responses and injectable drug and vaccine innovation. Read More
China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. Read More
McKinsey and Co. has taken the unusual step of apologizing for the consulting work it did for Purdue Pharma, which has entered into an $8 billion settlement with the Justice Department over its role in the opioid abuse crisis. Read More
Inovio has dosed the first participant in the phase 2 segment of its phase 2/3 trial evaluating COVID-19 vaccine candidate INO-4800, funded by the Department of Defense (DoD). Read More
Less than a month after receiving an Emergency Use Authorization (EUA) for rheumatoid arthritis drug Olumiant (baricitinib) to treat COVID-19, Eli Lilly is facing questions about the drug’s efficacy in treating the pandemic disease. Read More
Eli Lilly and healthcare company UnitedHealth are working together to conduct a pragmatic study of the American pharma titan’s COVID-19 antibody treatment, bamlanivimab (LY-CoV555), a therapy that received Emergency Use Authorization (EUA) from the FDA nearly a month ago. Read More
PhRMA and BIO have filed lawsuits in an attempt to thwart the Trump administration’s most favored nations policy, a drug pricing measure unpopular with the pharma industry that will soon come into effect, and the litigation is likely to delay the policy’s implementation. Read More